Gene therapy to treat ethanol-induced osteoporosis associated with aldehyde dehydrogenase 2 deficiency in post-menopausal east asian women
Active Project Grant Awarded Last action
- Award ID
- R42AA028465
- Recipient
-
Enyx Therapeutics LLC UEI PP93C8GM4JM5
- Awarding agency
-
National Institute on Alcohol Abuse and Alcoholism
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,045,526
Award facts
- Assistance listing
- 93.273 Alcohol Research Programs
- Completion date 88% complete
- Place of performance
- New York, NY 10001, USA
Award details come from USAspending.gov.
Description
- Abstract
- Enyx therapeutics, LLC, is an early-stage biotechnology company focused on using in vivo gene therapy technologies to treat hereditary disorders of unmet medical need. Enyx is developing an in vivo gene therapy strategy to mitigate the high risk for osteoporosis related HIP fracture in alcohol consuming post-menopausal east asian women with aldehyde dehydrogenase 2 deficiency (ALDH2D). ALDH2D is a hereditary disorder affecting 8% of the world population, and 35-45% of people of east asian background. ALDH2 is a key enzyme for ethanol metabolism; with ethanol ingestion, ALDH2 mutations result in systemic accumulation of toxic acetaldehyde. The most common variant is the ALDH2*2 allele (E487K). Heterozygotes have
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $791,929 | |
| Original award | $1,253,597 |
Quick answers
Who received award R42AA028465?
R42AA028465 was awarded to Enyx Therapeutics LLC by National Institute on Alcohol Abuse and Alcoholism (National Institutes of Health) on July 1, 2020.
How much is award R42AA028465 worth?
$2,045,526 has been obligated on R42AA028465.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award